Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Synovial Sarcoma, X Breakpoint 2 (SSX2) Peptide

SSX2 Reactivité: Humain Hôte: Synthetic BP, WB
N° du produit ABIN984471

Aperçu rapide pour Synovial Sarcoma, X Breakpoint 2 (SSX2) Peptide (ABIN984471)

Antigène

SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

Origine

Humain

Source

  • 2
Synthetic

Application

Blocking Peptide (BP), Western Blotting (WB)
  • Attributs du produit

    This is a synthetic peptide designed for use in combination with anti-SSX2 antibody (Catalog #: ARP37719_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.

    Purification

    Purified
  • Indications d'application

    Each Investigator should determine their own optimal working dilution for specific applications.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Concentration

    1 mg/mL

    Buffer

    Final peptide concentration is 1 mg/mL in PBS.

    Conseil sur la manipulation

    Avoid repeated freeze-thaw cycles.

    Stock

    -20 °C

    Stockage commentaire

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Antigène

    SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

    Sujet

    SSX2 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.

    Alias Symbols: HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX, SSX2B, CT5.2a

    Protein Interaction Partner: RAB3IP,SSX2IP,RNF2

    Protein Size: 223

    Poids moléculaire

    25 kDa

    ID gène

    6757

    NCBI Accession

    NM_003147, NP_003138
Vous êtes ici:
Chat with us!